0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global VEGF Inhibitors Market Research Report 2024
Published Date: August 2024
|
Report Code: QYRE-Auto-36Z17938
Home | Market Reports | Health| Health Conditions| Cancer
Global VEGF Inhibitors Market Research Report 2024
BUY CHAPTERS

Global VEGF Inhibitors Market Research Report 2024

Code: QYRE-Auto-36Z17938
Report
August 2024
Pages:89
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

VEGF Inhibitors Market

Vascular endothelial growth factor inhibitors,are a class of medications that work by blocking the action of vascular endothelial growth factor(VEGF).VEGF is a protein that plays a crucial role in the formation of new blood vessels(angiogenesis)in both normal and pathological conditions,such as cancer.In medical practice,VEGF inhibitors are primarily used as anti-angiogenic agents to treat cancers and certain eye conditions.
The global VEGF Inhibitors market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.
North American market for VEGF Inhibitors is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for VEGF Inhibitors is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of VEGF Inhibitors include Roche, Novartis, Coherus BioSciences, Bayer, Amneal Pharmaceuticals, Sanofi, Samsung Bioepis, Eli Lilly, Pfizer, Celltrion Healthcare, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for VEGF Inhibitors, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding VEGF Inhibitors.
The VEGF Inhibitors market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global VEGF Inhibitors market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the VEGF Inhibitors manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of VEGF Inhibitors Market Report

Report Metric Details
Report Name VEGF Inhibitors Market
Segment by Type
Segment by Application
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Roche, Novartis, Coherus BioSciences, Bayer, Amneal Pharmaceuticals, Sanofi, Samsung Bioepis, Eli Lilly, Pfizer, Celltrion Healthcare, Amgen, Chengdu Kanghong Pharmaceutical
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of VEGF Inhibitors manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of VEGF Inhibitors in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

Who are the main players in the VEGF Inhibitors Market report?

Ans: The main players in the VEGF Inhibitors Market are Roche, Novartis, Coherus BioSciences, Bayer, Amneal Pharmaceuticals, Sanofi, Samsung Bioepis, Eli Lilly, Pfizer, Celltrion Healthcare, Amgen, Chengdu Kanghong Pharmaceutical

What are the Application segmentation covered in the VEGF Inhibitors Market report?

Ans: The Applications covered in the VEGF Inhibitors Market report are Degenerative Eye Diseases, Cancer, Other

What are the Type segmentation covered in the VEGF Inhibitors Market report?

Ans: The Types covered in the VEGF Inhibitors Market report are Monoclonal Antibodies, Fusion Proteins

Recommended Reports

VEGF and Inhibitors

Monoclonal & Fusion

Ophthalmic & Antiangiogenic

1 VEGF Inhibitors Market Overview
1.1 Product Definition
1.2 VEGF Inhibitors by Type
1.2.1 Global VEGF Inhibitors Market Value Comparison by Type (2024-2030)
1.2.2 Monoclonal Antibodies
1.2.3 Fusion Proteins
1.3 VEGF Inhibitors by Application
1.3.1 Global VEGF Inhibitors Market Value by Application (2024-2030)
1.3.2 Degenerative Eye Diseases
1.3.3 Cancer
1.3.4 Other
1.4 Global VEGF Inhibitors Market Size Estimates and Forecasts
1.4.1 Global VEGF Inhibitors Revenue 2019-2030
1.4.2 Global VEGF Inhibitors Sales 2019-2030
1.4.3 Global VEGF Inhibitors Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 VEGF Inhibitors Market Competition by Manufacturers
2.1 Global VEGF Inhibitors Sales Market Share by Manufacturers (2019-2024)
2.2 Global VEGF Inhibitors Revenue Market Share by Manufacturers (2019-2024)
2.3 Global VEGF Inhibitors Average Price by Manufacturers (2019-2024)
2.4 Global Key Players of VEGF Inhibitors, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of VEGF Inhibitors, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of VEGF Inhibitors, Product Type & Application
2.7 Global Key Manufacturers of VEGF Inhibitors, Date of Enter into This Industry
2.8 Global VEGF Inhibitors Market Competitive Situation and Trends
2.8.1 Global VEGF Inhibitors Market Concentration Rate
2.8.2 The Global 5 and 10 Largest VEGF Inhibitors Players Market Share by Revenue
2.8.3 Global VEGF Inhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global VEGF Inhibitors Market Scenario by Region
3.1 Global VEGF Inhibitors Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global VEGF Inhibitors Sales by Region: 2019-2030
3.2.1 Global VEGF Inhibitors Sales by Region: 2019-2024
3.2.2 Global VEGF Inhibitors Sales by Region: 2025-2030
3.3 Global VEGF Inhibitors Revenue by Region: 2019-2030
3.3.1 Global VEGF Inhibitors Revenue by Region: 2019-2024
3.3.2 Global VEGF Inhibitors Revenue by Region: 2025-2030
3.4 North America VEGF Inhibitors Market Facts & Figures by Country
3.4.1 North America VEGF Inhibitors Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America VEGF Inhibitors Sales by Country (2019-2030)
3.4.3 North America VEGF Inhibitors Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe VEGF Inhibitors Market Facts & Figures by Country
3.5.1 Europe VEGF Inhibitors Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe VEGF Inhibitors Sales by Country (2019-2030)
3.5.3 Europe VEGF Inhibitors Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific VEGF Inhibitors Market Facts & Figures by Region
3.6.1 Asia Pacific VEGF Inhibitors Market Size by Region: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific VEGF Inhibitors Sales by Region (2019-2030)
3.6.3 Asia Pacific VEGF Inhibitors Revenue by Region (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America VEGF Inhibitors Market Facts & Figures by Country
3.7.1 Latin America VEGF Inhibitors Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America VEGF Inhibitors Sales by Country (2019-2030)
3.7.3 Latin America VEGF Inhibitors Revenue by Country
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa VEGF Inhibitors Market Facts & Figures by Country
3.8.1 Middle East and Africa VEGF Inhibitors Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa VEGF Inhibitors Sales by Country (2019-2030)
3.8.3 Middle East and Africa VEGF Inhibitors Revenue by Country
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global VEGF Inhibitors Sales by Type (2019-2030)
4.1.1 Global VEGF Inhibitors Sales by Type (2019-2024)
4.1.2 Global VEGF Inhibitors Sales by Type (2025-2030)
4.1.3 Global VEGF Inhibitors Sales Market Share by Type (2019-2030)
4.2 Global VEGF Inhibitors Revenue by Type (2019-2030)
4.2.1 Global VEGF Inhibitors Revenue by Type (2019-2024)
4.2.2 Global VEGF Inhibitors Revenue by Type (2025-2030)
4.2.3 Global VEGF Inhibitors Revenue Market Share by Type (2019-2030)
4.3 Global VEGF Inhibitors Price by Type (2019-2030)
5 Segment by Application
5.1 Global VEGF Inhibitors Sales by Application (2019-2030)
5.1.1 Global VEGF Inhibitors Sales by Application (2019-2024)
5.1.2 Global VEGF Inhibitors Sales by Application (2025-2030)
5.1.3 Global VEGF Inhibitors Sales Market Share by Application (2019-2030)
5.2 Global VEGF Inhibitors Revenue by Application (2019-2030)
5.2.1 Global VEGF Inhibitors Revenue by Application (2019-2024)
5.2.2 Global VEGF Inhibitors Revenue by Application (2025-2030)
5.2.3 Global VEGF Inhibitors Revenue Market Share by Application (2019-2030)
5.3 Global VEGF Inhibitors Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Roche
6.1.1 Roche Company Information
6.1.2 Roche Description and Business Overview
6.1.3 Roche VEGF Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Roche VEGF Inhibitors Product Portfolio
6.1.5 Roche Recent Developments/Updates
6.2 Novartis
6.2.1 Novartis Company Information
6.2.2 Novartis Description and Business Overview
6.2.3 Novartis VEGF Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Novartis VEGF Inhibitors Product Portfolio
6.2.5 Novartis Recent Developments/Updates
6.3 Coherus BioSciences
6.3.1 Coherus BioSciences Company Information
6.3.2 Coherus BioSciences Description and Business Overview
6.3.3 Coherus BioSciences VEGF Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Coherus BioSciences VEGF Inhibitors Product Portfolio
6.3.5 Coherus BioSciences Recent Developments/Updates
6.4 Bayer
6.4.1 Bayer Company Information
6.4.2 Bayer Description and Business Overview
6.4.3 Bayer VEGF Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Bayer VEGF Inhibitors Product Portfolio
6.4.5 Bayer Recent Developments/Updates
6.5 Amneal Pharmaceuticals
6.5.1 Amneal Pharmaceuticals Company Information
6.5.2 Amneal Pharmaceuticals Description and Business Overview
6.5.3 Amneal Pharmaceuticals VEGF Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Amneal Pharmaceuticals VEGF Inhibitors Product Portfolio
6.5.5 Amneal Pharmaceuticals Recent Developments/Updates
6.6 Sanofi
6.6.1 Sanofi Company Information
6.6.2 Sanofi Description and Business Overview
6.6.3 Sanofi VEGF Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Sanofi VEGF Inhibitors Product Portfolio
6.6.5 Sanofi Recent Developments/Updates
6.7 Samsung Bioepis
6.7.1 Samsung Bioepis Company Information
6.7.2 Samsung Bioepis Description and Business Overview
6.7.3 Samsung Bioepis VEGF Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.7.4 Samsung Bioepis VEGF Inhibitors Product Portfolio
6.7.5 Samsung Bioepis Recent Developments/Updates
6.8 Eli Lilly
6.8.1 Eli Lilly Company Information
6.8.2 Eli Lilly Description and Business Overview
6.8.3 Eli Lilly VEGF Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Eli Lilly VEGF Inhibitors Product Portfolio
6.8.5 Eli Lilly Recent Developments/Updates
6.9 Pfizer
6.9.1 Pfizer Company Information
6.9.2 Pfizer Description and Business Overview
6.9.3 Pfizer VEGF Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Pfizer VEGF Inhibitors Product Portfolio
6.9.5 Pfizer Recent Developments/Updates
6.10 Celltrion Healthcare
6.10.1 Celltrion Healthcare Company Information
6.10.2 Celltrion Healthcare Description and Business Overview
6.10.3 Celltrion Healthcare VEGF Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Celltrion Healthcare VEGF Inhibitors Product Portfolio
6.10.5 Celltrion Healthcare Recent Developments/Updates
6.11 Amgen
6.11.1 Amgen Company Information
6.11.2 Amgen Description and Business Overview
6.11.3 Amgen VEGF Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Amgen VEGF Inhibitors Product Portfolio
6.11.5 Amgen Recent Developments/Updates
6.12 Chengdu Kanghong Pharmaceutical
6.12.1 Chengdu Kanghong Pharmaceutical Company Information
6.12.2 Chengdu Kanghong Pharmaceutical Description and Business Overview
6.12.3 Chengdu Kanghong Pharmaceutical VEGF Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Chengdu Kanghong Pharmaceutical VEGF Inhibitors Product Portfolio
6.12.5 Chengdu Kanghong Pharmaceutical Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 VEGF Inhibitors Industry Chain Analysis
7.2 VEGF Inhibitors Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 VEGF Inhibitors Production Mode & Process
7.4 VEGF Inhibitors Sales and Marketing
7.4.1 VEGF Inhibitors Sales Channels
7.4.2 VEGF Inhibitors Distributors
7.5 VEGF Inhibitors Customers
8 VEGF Inhibitors Market Dynamics
8.1 VEGF Inhibitors Industry Trends
8.2 VEGF Inhibitors Market Drivers
8.3 VEGF Inhibitors Market Challenges
8.4 VEGF Inhibitors Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
 Table 1. Global VEGF Inhibitors Market Value Comparison by Type (2024-2030) & (US$ Million)
 Table 2. Global VEGF Inhibitors Market Value by Application (2024-2030) & (US$ Million)
 Table 3. Global VEGF Inhibitors Market Competitive Situation by Manufacturers in 2023
 Table 4. Global VEGF Inhibitors Sales (K Units) of Key Manufacturers (2019-2024)
 Table 5. Global VEGF Inhibitors Sales Market Share by Manufacturers (2019-2024)
 Table 6. Global VEGF Inhibitors Revenue (US$ Million) by Manufacturers (2019-2024)
 Table 7. Global VEGF Inhibitors Revenue Share by Manufacturers (2019-2024)
 Table 8. Global Market VEGF Inhibitors Average Price (US$/Unit) of Key Manufacturers (2019-2024)
 Table 9. Global Key Players of VEGF Inhibitors, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of VEGF Inhibitors, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of VEGF Inhibitors, Product Type & Application
 Table 12. Global Key Manufacturers of VEGF Inhibitors, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global VEGF Inhibitors by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in VEGF Inhibitors as of 2023)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global VEGF Inhibitors Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
 Table 17. Global VEGF Inhibitors Sales by Region (2019-2024) & (K Units)
 Table 18. Global VEGF Inhibitors Sales Market Share by Region (2019-2024)
 Table 19. Global VEGF Inhibitors Sales by Region (2025-2030) & (K Units)
 Table 20. Global VEGF Inhibitors Sales Market Share by Region (2025-2030)
 Table 21. Global VEGF Inhibitors Revenue by Region (2019-2024) & (US$ Million)
 Table 22. Global VEGF Inhibitors Revenue Market Share by Region (2019-2024)
 Table 23. Global VEGF Inhibitors Revenue by Region (2025-2030) & (US$ Million)
 Table 24. Global VEGF Inhibitors Revenue Market Share by Region (2025-2030)
 Table 25. North America VEGF Inhibitors Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 26. North America VEGF Inhibitors Sales by Country (2019-2024) & (K Units)
 Table 27. North America VEGF Inhibitors Sales by Country (2025-2030) & (K Units)
 Table 28. North America VEGF Inhibitors Revenue by Country (2019-2024) & (US$ Million)
 Table 29. North America VEGF Inhibitors Revenue by Country (2025-2030) & (US$ Million)
 Table 30. Europe VEGF Inhibitors Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 31. Europe VEGF Inhibitors Sales by Country (2019-2024) & (K Units)
 Table 32. Europe VEGF Inhibitors Sales by Country (2025-2030) & (K Units)
 Table 33. Europe VEGF Inhibitors Revenue by Country (2019-2024) & (US$ Million)
 Table 34. Europe VEGF Inhibitors Revenue by Country (2025-2030) & (US$ Million)
 Table 35. Asia Pacific VEGF Inhibitors Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
 Table 36. Asia Pacific VEGF Inhibitors Sales by Region (2019-2024) & (K Units)
 Table 37. Asia Pacific VEGF Inhibitors Sales by Region (2025-2030) & (K Units)
 Table 38. Asia Pacific VEGF Inhibitors Revenue by Region (2019-2024) & (US$ Million)
 Table 39. Asia Pacific VEGF Inhibitors Revenue by Region (2025-2030) & (US$ Million)
 Table 40. Latin America VEGF Inhibitors Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 41. Latin America VEGF Inhibitors Sales by Country (2019-2024) & (K Units)
 Table 42. Latin America VEGF Inhibitors Sales by Country (2025-2030) & (K Units)
 Table 43. Latin America VEGF Inhibitors Revenue by Country (2019-2024) & (US$ Million)
 Table 44. Latin America VEGF Inhibitors Revenue Market Share by Country (2019-2024)
 Table 45. Middle East and Africa VEGF Inhibitors Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 46. Middle East and Africa VEGF Inhibitors Sales by Country (2019-2024) & (K Units)
 Table 47. Middle East and Africa VEGF Inhibitors Sales by Country (2025-2030) & (K Units)
 Table 48. Middle East and Africa VEGF Inhibitors Revenue by Country (2019-2024) & (US$ Million)
 Table 49. Middle East and Africa VEGF Inhibitors Revenue by Country (2025-2030) & (US$ Million)
 Table 50. Global VEGF Inhibitors Sales (K Units) by Type (2019-2024)
 Table 51. Global VEGF Inhibitors Sales (K Units) by Type (2025-2030)
 Table 52. Global VEGF Inhibitors Sales Market Share by Type (2019-2024)
 Table 53. Global VEGF Inhibitors Sales Market Share by Type (2025-2030)
 Table 54. Global VEGF Inhibitors Revenue (US$ Million) by Type (2019-2024)
 Table 55. Global VEGF Inhibitors Revenue (US$ Million) by Type (2025-2030)
 Table 56. Global VEGF Inhibitors Revenue Market Share by Type (2019-2024)
 Table 57. Global VEGF Inhibitors Revenue Market Share by Type (2025-2030)
 Table 58. Global VEGF Inhibitors Price (US$/Unit) by Type (2019-2024)
 Table 59. Global VEGF Inhibitors Price (US$/Unit) by Type (2025-2030)
 Table 60. Global VEGF Inhibitors Sales (K Units) by Application (2019-2024)
 Table 61. Global VEGF Inhibitors Sales (K Units) by Application (2025-2030)
 Table 62. Global VEGF Inhibitors Sales Market Share by Application (2019-2024)
 Table 63. Global VEGF Inhibitors Sales Market Share by Application (2025-2030)
 Table 64. Global VEGF Inhibitors Revenue (US$ Million) by Application (2019-2024)
 Table 65. Global VEGF Inhibitors Revenue (US$ Million) by Application (2025-2030)
 Table 66. Global VEGF Inhibitors Revenue Market Share by Application (2019-2024)
 Table 67. Global VEGF Inhibitors Revenue Market Share by Application (2025-2030)
 Table 68. Global VEGF Inhibitors Price (US$/Unit) by Application (2019-2024)
 Table 69. Global VEGF Inhibitors Price (US$/Unit) by Application (2025-2030)
 Table 70. Roche Company Information
 Table 71. Roche Description and Business Overview
 Table 72. Roche VEGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 73. Roche VEGF Inhibitors Product
 Table 74. Roche Recent Developments/Updates
 Table 75. Novartis Company Information
 Table 76. Novartis Description and Business Overview
 Table 77. Novartis VEGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 78. Novartis VEGF Inhibitors Product
 Table 79. Novartis Recent Developments/Updates
 Table 80. Coherus BioSciences Company Information
 Table 81. Coherus BioSciences Description and Business Overview
 Table 82. Coherus BioSciences VEGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 83. Coherus BioSciences VEGF Inhibitors Product
 Table 84. Coherus BioSciences Recent Developments/Updates
 Table 85. Bayer Company Information
 Table 86. Bayer Description and Business Overview
 Table 87. Bayer VEGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 88. Bayer VEGF Inhibitors Product
 Table 89. Bayer Recent Developments/Updates
 Table 90. Amneal Pharmaceuticals Company Information
 Table 91. Amneal Pharmaceuticals Description and Business Overview
 Table 92. Amneal Pharmaceuticals VEGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 93. Amneal Pharmaceuticals VEGF Inhibitors Product
 Table 94. Amneal Pharmaceuticals Recent Developments/Updates
 Table 95. Sanofi Company Information
 Table 96. Sanofi Description and Business Overview
 Table 97. Sanofi VEGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 98. Sanofi VEGF Inhibitors Product
 Table 99. Sanofi Recent Developments/Updates
 Table 100. Samsung Bioepis Company Information
 Table 101. Samsung Bioepis Description and Business Overview
 Table 102. Samsung Bioepis VEGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 103. Samsung Bioepis VEGF Inhibitors Product
 Table 104. Samsung Bioepis Recent Developments/Updates
 Table 105. Eli Lilly Company Information
 Table 106. Eli Lilly Description and Business Overview
 Table 107. Eli Lilly VEGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 108. Eli Lilly VEGF Inhibitors Product
 Table 109. Eli Lilly Recent Developments/Updates
 Table 110. Pfizer Company Information
 Table 111. Pfizer Description and Business Overview
 Table 112. Pfizer VEGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 113. Pfizer VEGF Inhibitors Product
 Table 114. Pfizer Recent Developments/Updates
 Table 115. Celltrion Healthcare Company Information
 Table 116. Celltrion Healthcare Description and Business Overview
 Table 117. Celltrion Healthcare VEGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 118. Celltrion Healthcare VEGF Inhibitors Product
 Table 119. Celltrion Healthcare Recent Developments/Updates
 Table 120. Amgen Company Information
 Table 121. Amgen Description and Business Overview
 Table 122. Amgen VEGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 123. Amgen VEGF Inhibitors Product
 Table 124. Amgen Recent Developments/Updates
 Table 125. Chengdu Kanghong Pharmaceutical Company Information
 Table 126. Chengdu Kanghong Pharmaceutical Description and Business Overview
 Table 127. Chengdu Kanghong Pharmaceutical VEGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 128. Chengdu Kanghong Pharmaceutical VEGF Inhibitors Product
 Table 129. Chengdu Kanghong Pharmaceutical Recent Developments/Updates
 Table 130. Key Raw Materials Lists
 Table 131. Raw Materials Key Suppliers Lists
 Table 132. VEGF Inhibitors Distributors List
 Table 133. VEGF Inhibitors Customers List
 Table 134. VEGF Inhibitors Market Trends
 Table 135. VEGF Inhibitors Market Drivers
 Table 136. VEGF Inhibitors Market Challenges
 Table 137. VEGF Inhibitors Market Restraints
 Table 138. Research Programs/Design for This Report
 Table 139. Key Data Information from Secondary Sources
 Table 140. Key Data Information from Primary Sources
 Table 141. Authors List of This Report


List of Figures
 Figure 1. Product Picture of VEGF Inhibitors
 Figure 2. Global VEGF Inhibitors Market Value Comparison by Type (2024-2030) & (US$ Million)
 Figure 3. Global VEGF Inhibitors Market Share by Type: 2023 & 2030
 Figure 4. Monoclonal Antibodies Product Picture
 Figure 5. Fusion Proteins Product Picture
 Figure 6. Global VEGF Inhibitors Market Value by Application (2024-2030) & (US$ Million)
 Figure 7. Global VEGF Inhibitors Market Share by Application: 2023 & 2030
 Figure 8. Degenerative Eye Diseases
 Figure 9. Cancer
 Figure 10. Other
 Figure 11. Global VEGF Inhibitors Revenue, (US$ Million), 2019 VS 2023 VS 2030
 Figure 12. Global VEGF Inhibitors Market Size (2019-2030) & (US$ Million)
 Figure 13. Global VEGF Inhibitors Sales (2019-2030) & (K Units)
 Figure 14. Global VEGF Inhibitors Average Price (US$/Unit) & (2019-2030)
 Figure 15. VEGF Inhibitors Report Years Considered
 Figure 16. VEGF Inhibitors Sales Share by Manufacturers in 2023
 Figure 17. Global VEGF Inhibitors Revenue Share by Manufacturers in 2023
 Figure 18. Global 5 and 10 Largest VEGF Inhibitors Players: Market Share by Revenue in VEGF Inhibitors in 2023
 Figure 19. VEGF Inhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
 Figure 20. Global VEGF Inhibitors Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
 Figure 21. North America VEGF Inhibitors Sales Market Share by Country (2019-2030)
 Figure 22. North America VEGF Inhibitors Revenue Market Share by Country (2019-2030)
 Figure 23. United States VEGF Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 24. Canada VEGF Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 25. Europe VEGF Inhibitors Sales Market Share by Country (2019-2030)
 Figure 26. Europe VEGF Inhibitors Revenue Market Share by Country (2019-2030)
 Figure 27. Germany VEGF Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 28. France VEGF Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 29. U.K. VEGF Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 30. Italy VEGF Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 31. Russia VEGF Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 32. Asia Pacific VEGF Inhibitors Sales Market Share by Region (2019-2030)
 Figure 33. Asia Pacific VEGF Inhibitors Revenue Market Share by Region (2019-2030)
 Figure 34. China VEGF Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 35. Japan VEGF Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 36. South Korea VEGF Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 37. India VEGF Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 38. Australia VEGF Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 39. China Taiwan VEGF Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 40. Southeast Asia VEGF Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 41. Latin America VEGF Inhibitors Sales Market Share by Country (2019-2030)
 Figure 42. Mexico VEGF Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 43. Brazil VEGF Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 44. Argentina VEGF Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 45. Colombia VEGF Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 46. Middle East and Africa VEGF Inhibitors Sales Market Share by Country (2019-2030)
 Figure 47. Middle East and Africa VEGF Inhibitors Revenue Market Share by Country (2019-2030)
 Figure 48. Turkey VEGF Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 49. Saudi Arabia VEGF Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 50. UAE VEGF Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 51. Global Sales Market Share of VEGF Inhibitors by Type (2019-2030)
 Figure 52. Global Revenue Market Share of VEGF Inhibitors by Type (2019-2030)
 Figure 53. Global VEGF Inhibitors Price (US$/Unit) by Type (2019-2030)
 Figure 54. Global Sales Market Share of VEGF Inhibitors by Application (2019-2030)
 Figure 55. Global Revenue Market Share of VEGF Inhibitors by Application (2019-2030)
 Figure 56. Global VEGF Inhibitors Price (US$/Unit) by Application (2019-2030)
 Figure 57. VEGF Inhibitors Value Chain
 Figure 58. VEGF Inhibitors Production Process
 Figure 59. Channels of Distribution (Direct Vs Distribution)
 Figure 60. Bottom-up and Top-down Approaches for This Report
 Figure 61. Data Triangulation
 Figure 62. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Lukasiewicz Research Network

RELATED REPORTS

Global Fixation Device for Radiotherapy Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-4H16852
Thu Sep 25 00:00:00 UTC 2025

Add to Cart

Global Group A Streptococcus for Injection Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-37K16619
Thu Sep 25 00:00:00 UTC 2025

Add to Cart

Global Boron Neutron Capture Therapy System Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-30U16301
Thu Sep 25 00:00:00 UTC 2025

Add to Cart

Global Radioactive Glass Microsphere Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-2G16953
Thu Sep 25 00:00:00 UTC 2025

Add to Cart